Back to Journals » Blood and Lymphatic Cancer: Targets and Therapy » Volume 15 » default
Blood and Lymphatic Cancer: Targets and Therapy
- View all (140)
- Volume 16, 2026 (14)
- Volume 15, 2025 (19)
- Volume 14, 2024 (6)
- Volume 13, 2023 (7)
- Volume 12, 2022 (12)
- Volume 11, 2021 (6)
- Volume 10, 2020 (2)
- Volume 9, 2019 (7)
- Volume 8, 2018 (7)
- Volume 7, 2017 (8)
- Volume 6, 2016 (5)
- Volume 5, 2015 (11)
- Volume 4, 2014 (13)
- Volume 3, 2013 (6)
- Volume 2, 2012 (12)
- Volume 1, 2011 (5)
Archive: Volume 15, 2025
Expression and Clinical Significance of BCL2 Interacting Protein 3 Like (BNIP3L) in Serum of Patients with MM
Nong Y, Xiong Z, Wang Q, Gu M, Zheng Y, Wang Y, Wu J, Huang C, Li Z, Luo J, Ling Z, Li R
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:247-264
Published Date: 17 December 2025
LRG1 Drives AML Progression by Disrupting Myeloid Progenitor Regulation
Guo R, Wu P, Yao S, Liu F
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:235-246
Published Date: 17 December 2025
Alantolactone Inhibits Double Expression Lymphoma via Dual-Targeted Glycogen Synthase Kinase 3 Beta and B-Cell Lymphoma2
Chen J, Liao Q, Yang S, Bian J, Li X, Zhao L, Wen D, Bai D, Yu C, Zhou C, Xu Z
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:217-233
Published Date: 12 December 2025
Phase II Trial of an Orelabrutinib-Based Combination Therapy in Newly Diagnosed Primary Central Nervous System Lymphoma
Zhao Y, Liu X, He Q, Yu Y, Xu L, Sun C, Liu G, Wang L, Ma J
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:203-216
Published Date: 6 December 2025
Venetoclax Plus Blinatumoma as First Line Therapy for Newly Diagnosed Ph-Negative B-Cell Acute Lymphoblastic Leukemia
Lei Y, Zhao X, Huang H, Duan L, Xu J, Miao K, Zhao H, Qiao C, Hong M, Qian S, Fan L, Zhu Y
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:193-202
Published Date: 5 November 2025
The Ongoing Challenges of Managing Cytopenic Myelofibrosis in 2025: The Emergence of Non-JAK Inhibitor Therapies
Reynolds SB, Komrokji R, Kuykendall AT
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:181-192
Published Date: 24 September 2025
Comprehensive Analysis of Tumor Microenvironment and PD-L1 Expression Associations with Clinicopathological Features and Prognosis in Diffuse Large B-Cell Lymphoma
Xie YL, Ke LF, Zhang WW, Kang F, Lu SY, Wu CY, Zhu HH, Wang JC, Chen G, Chen YP
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:167-179
Published Date: 6 September 2025
Comprehensive Evaluation of Drug-Related Problems and Pharmacotherapy Patterns in Non-Hodgkin’s Lymphoma Patients in Yemen
Battah MM, Zainal H, Ibrahim DA, Md Hanafiah NH, Syed Sulaiman SA
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:149-166
Published Date: 4 September 2025
Serum ATIC Expression as a Novel Diagnostic and Prognostic Biomarker in Multiple Myeloma Patients
Gu M, Zheng Y, Wang Y, Wang Q, Wu J, Xiong Z, Nong Y, Huang C, Li Z, Luo J, Ling Z, Li R
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:133-147
Published Date: 30 August 2025
Neutrophil-Related Genes Predict Prognosis and Contribute to Immunosuppression in Acute Myeloid Leukemia
Zhang D, Li Y, Liu T, Liu X, Zhang J
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:115-132
Published Date: 18 August 2025
Optimizing Timing and Preparation for Allogeneic Hematopoietic Stem Cell Transplantation in Higher-Risk Myelodysplastic Syndromes
Geng L, Chen E, Ji Y, Liu H, Sun Z
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:103-113
Published Date: 1 August 2025
Clinical Characteristics, Prognostic Risk Factors, and Primary Treatment for Elderly Patients with Primary Central Nervous System Lymphoma: A Seer Database-Based Research
Zhang M, Yang R, Du Y, Feng H, Liu Y, Liu H, Wu D, Niu F, He P
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:85-101
Published Date: 7 July 2025
Deep Dive into Targeted Therapies: Understanding IDH1-Mutant AML Treatments [Podcast]
Zeidan AM, DiNardo C
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:77-83
Published Date: 2 July 2025
Advancing AML Treatment: Evidence-Based Regimens and Guideline Updates for Targeted Treatments in R/R AML [Podcast]
Zeidan AM, Wang E
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:69-75
Published Date: 2 July 2025
Advancing Leukemia Diagnosis and Treatment: WHO-Supported Laboratory Innovations in Africa- A Narrative Review
Obeagu EI
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:47-67
Published Date: 24 June 2025
Unveiling the Mysteries of Molecular Testing in AML: A Guide for Oncologists [Podcast]
Zeidan AM, Loghavi S
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:39-45
Published Date: 21 June 2025
A Monocyte-Driven Prognostic Model for Multiple Myeloma: Multi-Omics and Machine Learning Insights
Xie L, Gao M, Tan S, Zhou Y, Liu J, Wang L, Li X
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:21-37
Published Date: 16 June 2025
An Updated Indirect Comparison of Elranatamab Versus a Real-World External Control Arm in Triple-Class Refractory Multiple Myeloma
Costa LJ, LeBlanc TW, Tesch H, Sonneveld P, Johnson SM, Vekeman F, Hlavacek P, Meche A, Kim CH, Cislo P, Hughes DM, Nador G, DiBonaventura M
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:11-20
Published Date: 5 June 2025
T-Cell Engagers In Multiple Myeloma: A Clinical Review
Al-Jarrad A, Alouch SS, Chawla Y, Gonsalves WI
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:1-10
Published Date: 24 March 2025